Related references
Note: Only part of the references are listed.The current status of anti-GPCR drugs against different cancers
Sana Usman et al.
JOURNAL OF PHARMACEUTICAL ANALYSIS (2020)
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2020)
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Aena Patel et al.
CANCERS (2020)
G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers
Nadia Arang et al.
FEBS LETTERS (2020)
GPCRomics: An Approach to Discover GPCR Drug Targets
Paul A. Insel et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors
Krishna Sriram et al.
PLOS BIOLOGY (2019)
Targeting G protein-coupled receptor signalling by blocking G proteins
Adrian P. Campbell et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
GPCR Modulation in Breast Cancer
Rosamaria Lappano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
Ariella B. Hanker et al.
CANCER RESEARCH (2017)
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Angel Guerrero-Zotano et al.
CANCER AND METASTASIS REVIEWS (2016)
GPCR Signaling Mediates Tumor Metastasis via PI3Kβ
Bassem D. Khalil et al.
CANCER RESEARCH (2016)
Proteogenomics connects somatic mutations to signalling in breast cancer
Philipp Mertins et al.
NATURE (2016)
Upregulated WDR26 serves as a scaffold to coordinate PI3K/AKT pathway-driven breast cancer cell growth, migration, and invasion
Yuanchao Ye et al.
ONCOTARGET (2016)
Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research
Zhixiang Wang
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
N. Elster et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+breast cancer cells
Brent N. Rexer et al.
BREAST CANCER RESEARCH (2014)
Molecular targeting of Gα and Gβγ subunits: a potential approach for cancer therapeutics
Alan V. Smrcka
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Generation of a Novel MMTV-tTA Transgenic Mouse Strain for the Targeted Expression of Genes in the Embryonic and Postnatal Mammary Gland
Kazuhito Sakamoto et al.
PLOS ONE (2012)
A Critical Role of Gβγ in Tumorigenesis and Metastasis of Breast Cancer
Xiaoyun Tang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Blockade of Receptor-Activated Gi Signaling in Osteoblasts In Vivo Leads to Site-Specific Increases in Cortical and Cancellous Bone Formation
Susan M. Millard et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
LPA1-Induced Migration Requires Nonmuscle Myosin II Light Chain Phosphorylation in Breast Cancer Cells
Jong Hyun Kim et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Trastuzumab resistance: all roads lead to SRC
Senthil K. Muthuswamy
NATURE MEDICINE (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
Molecular basis of a novel oncogenic mutation in GNAO1
M. Garcia-Marcos et al.
ONCOGENE (2011)
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
B. N. Rexer et al.
ONCOGENE (2011)
A Synthetic Biology Approach Reveals a CXCR4-G13-RhoSignaling Axis Driving Transendothelial Migration of Metastatic Breast Cancer Cells
Hiroshi Yagi et al.
SCIENCE SIGNALING (2011)
AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
D. Mark Hickinson et al.
CLINICAL CANCER RESEARCH (2010)
Gβγ Signaling Promotes Breast Cancer Cell Migration and Invasion
Joseph K. Kirui et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Diverse somatic mutation patterns and pathway alterations in human cancers
Zhengyan Kan et al.
NATURE (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Breast Cancer Migration and Invasion Depend on Proteasome Degradation of Regulator of G-Protein Signaling 4
Yan Xie et al.
CANCER RESEARCH (2009)
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Evelyn Yao et al.
CLINICAL CANCER RESEARCH (2009)
HER-2 Signaling and Inhibition in Breast Cancer
B. C. Browne et al.
CURRENT CANCER DRUG TARGETS (2009)
Heterotrimeric G protein activation by G-protein-coupled receptors
William M. Oldham et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion
P. Arora et al.
ONCOGENE (2008)
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor
Jitesh P. Jani et al.
CANCER RESEARCH (2007)
Endothelial β2 adrenergic signaling to AKT:: Role of Gi and SRC
Michele Ciccarelli et al.
CELLULAR SIGNALLING (2007)
TheEGF receptor family: spearheading a merger of signaling and therapeutics
Erez M. Bublil et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Differential targeting of Gβγ-subunit signaling with small molecules
TM Bonacci et al.
SCIENCE (2006)
CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A
PP Manna et al.
CANCER RESEARCH (2004)
β-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases
J Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The bacterial toxin toolkit
G Schiavo et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade
J Andreev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation
PT Ram et al.
ONCOGENE (2001)
Src tyrosine kinase is a novel direct effector of G proteins
YC Ma et al.
CELL (2000)
Share Paper
